BIOSCIENCE AMERICAS....SOLUTIONS FOR A HEALTHIER WORLD

BIOSCIENCE AMERICAS IS THE INTERNATIONAL DEVELOPMENT PARTNER OF THE GLOBAL INSTITUTE OF

STEM CELL THERAPY AND RESEARCH

Based at the University of California in San Diego, GIOSTAR is recognized

as one of the world’s leading stem cell research laboratories. Over the

years, they have been the beneficiary of more than $400 million in research

grants, endowment contributions and legislative appropriations. They

receive more than $50 million a year in on-going funding commitments.

GIOSTAR’s scientists are associated with many leading medical research

universities and institutions.

Bioscience Americas and GIOSTAR have entered into a Joint Venture

Agreement to own and operate a for-profit treatment wellness center

in Medellin, Colombia. Bioscience and GIOSTAR intend to participate in

additional joint ventures to own and operate for-profit clinics in Brazil, Chile

and eventually the United States.

Starting from this position as one of the world’s most respected stem

cell research consortiums, Bioscience and GIOSTAR intend to build and

promote the GIOSTAR brand as the world’s most recognized provider of

stem cell based treatments. This strategy is supported by the paradigm

shift occurring in health care today – toward a more patient centered focus

on treating diseases through a mastery of science as opposed to surgery

and symptom treatment with drugs.

THE GLOBAL INSTITUTE OF STEM CELL THERAPY AND RESEARCH

GIOSTAR’s scientists and researchers are associated with many leading

universities, research institutions, and hospitals including:

nUniversity of California at San Diego

nUniversity of California at Irvine

nUniversity of California at Los Angeles

nNational Research Institute, Japan

nUniversity Eye Hospital, Germany

nNansai Hospital, Japan

nVanderbilt University, Nashville

nCase Western Reserve University, Cleveland

nHarvard Medical School

nBurnham Research Institute, San Diego

nSalk Institute for Biological Studies, La Jolla, California

Our continuing research efforts provide our patients with the latest in

stem cell treatment care.

GIOSTAR’S UNIVERSITY AFFILIATIONS

FOR ADDITIONAL INFORMATION PLEASE CONTACT BIOSCIENCE AMERICAS, LLC(888) 623-0337 | BIOSCIENCEAMERICAS.COM

IS BRINGING STEM CELL TECHNOLOGY, SCIENCE AND TREATMENT TO THE MARKETPLACE.

GIOSTAR is one of the world’s leading adult stem cell research laboratories. Every year more than $50 million is invested in continued research providing solutions for life threatening diseases and illnesses. To date, Bioscience Americas and GIOSTAR have been the beneficiary of more than $400 million in research grants, endowment contributions and legislative appropriations.

GIOSTAR scientists are associated with many leading medical research universities including the University of California at San Diego and Los Angeles and Harvard University.

Bioscience Americas has teamed with GIOSTAR to own and operate for-profit rejuvenation and regeneration wellness centers throughout the world employing the FDA approved adult stem cell protocols and procedures created by GIOSTAR and its research partners.

nBacked by more than $400 million and 15 years of stem cell research and development.

n$50 million in annual research commitments.

nFDA approved treatments and clinical trials.

nParadigm shift in healthcare strategy and delivery.

nAging population’s need for GIOSTAR/BIOSCIENCE AMERICAS services.

n$86 billion market in South America alone.

nSuccessful delivery of stem cell services since 2011.

nMore than 4,000 patients successfully treated.

nWorld’s leading stem cell research team.

nAssociated with major medical research universities and institutions throughout the world.

nExceptional return on investment projected.

© Copyright 2015 Bioscience Americas, LLC.

THE GIOSTAR/BIOSCIENCE AMERICAS TEAM

Investment Total Investor Return

Allocation Per Unit

Allocation Per Year Annual %

Year 1

$100,000

Year 2

$100,000

Year 3

$100,000

Year 4

$100,000

Year 5

$100,000

Total 5

Year Return

Investment Total Investor Return

Allocation Per Unit

Allocation Per Year Annual %

Year 1

$250,000

Year 2

$250,000

Year 3

$250,000

Year 4

$250,000

Year 5

$250,000

Total 5

Year Return

Investment Total Investor Return

Allocation Per Unit

Allocation Per Year Annual %

Year 1

$1,000,000

Year 2

$1,000,000

Year 3

$1,000,000

Year 4

$1,000,000

Year 5

$1,000,000

Total 5

Year Return255%$23,255,964 $15,504 $2,550,398

68%

$13,032,147 $8,688 $868,810 $1,550,398 155%

$7,162,043 $4,775 $477,470 $681,58848%

87%

155%

4%

$2,450,734 $1,634 $163,382 $204,118 20%

$611,040 $407 $40,736 $40,7364%

16%

255%

Total Return on Investment (ROI)

-$71,838 -$48 -$4,789 $0 0%

$23,255,964 $15,504 $387,599 $637,599155%

0%

68%

$13,032,147 $8,688 $217,202 $387,599 155%

$7,162,043 $4,775 $119,367 $170,39748%

87%

4%

$2,450,734 $1,634 $40,846 $51,030 20%

$611,040 $407 $10,184 $10,1844%

16%

87%

48%

Total Return on Investment (ROI)

-$71,838 -$48 -$1,197 $0 0%

155% 255%$23,255,964 $15,504 $155,040 $255,040

Total Return on Investment (ROI)

-$71,838 -$48 -$479 0% 0%$0

4%

$2,450,734 $1,634 $16,338 20%

$611,040 $407 $4,074 $4,074

$20,412

4%

16%

0%

68%

$13,032,147 8,688 $86,881 155%

$7,162,043 $4,775 $47,747 $68,159

$155,040

BIOSCIENCE AMERICAS....SOLUTIONS FOR A HEALTHIER WORLD

INVESTORPROJECTED

ALLOCATION

Alzheimer‘s

Anti-Aging Treatments

Autism

Cerebral Palsy

Erectile dysfunction

Failed Back Surgery

Syndrome

or Postnucleotomy

Liver diseases

Macular degeneration

Neuropathy

Osteoarthritis

Paralysis

Parkinson‘s

Retinal Transplant

Spinal Cord Injuries

Strokes

Skin Burns

Spinal muscular atrophy

(SMA)

Stem Cell Therapy Under

Development

This material includes “forward-looking statements” from the Company that may or may not materialize and recipients are cautioned not to place undue reliance upon them. It is important to note that actual results could differ materially from those in such “forward-looking statements” and “forward-looking statements” are inherently subject to risks and uncertainties. This material does not constitute an offer to sell or a solicitation of an offer to buy any security. Such offers can be made only by the confidential Private Placement Memorandum (the“Memorandum”) which accompanies this material. This material cannot and does not replace the Memorandum and is qualified in its entirety by the Memorandum. All potential investors must read the Memorandum and no person may invest without acknowledging receipt and complete review of the Memorandum.

THE GIOSTAR/BIOSCIENCE AMERICAS TEAMIS BRINGING STEM CELL TECHNOLOGY, SCIENCE AND TREATMENT TO THE MARKETPLACE.

GIOSTAR is one of the world’s leading adult stem cell research laboratories. Every year more than $50 million is invested in continued research providing solutions for life threatening diseases and illnesses.

more than $400 million in research grants, endowment contributions and legislative appropriations.

GIOSTAR scientists are associated with many leading medical research universities including the University of California at San Diego and Los Angeles and Harvard University.

Bioscience Americas has teamed with GIOSTAR to own and operate

the world employing the FDA approved adult stem cell protocols and procedures created by GIOSTAR and its research partners.

Backed by more than $400 million and 15 years of stem cell research and development.

$50 million in annual research commitments.

FDA approved treatments and clinical trials.

Paradigm shift in healthcare strategy and delivery.

Aging population’s need for GIOSTAR/BIOSCIENCE AMERICAS services.

$86 billion market in South America alone.

Successful delivery of stem cell services since 2011.

More than 4,000 patients successfully treated.

World’s leading stem cell research team.

Associated with major medical research universities and institutions throughout the world.

Exceptional return on investment projected.

iTem res experum

Diabetes Type 1 and 2

Lupus

Multiple Sclerosis

Crohn’s Disease

Vasculitis

Scleroderma

Myasthenia Gravis

Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease)

Kidney Disease

Lymphoma

Healthcare, alternative medicine, nutrition, and cosmetics are large, booming markets in the western hemisphere. People in these markets now embrace stem cell treatments and therapeutics and other alternative means for health and beauty. GIOSTAR has the ability to deliver the most efficacious services on the market, doing so at prices that are affordable. In many instances, treatments are covered by the patient’s medical insurance.

GIOSTAR has also successfully treated other illnesses including sickle cell anemia, spinal cord injuries and burns.

The GIOSTAR/BIOSCIENCE AMERICAS Joint Venture in South America will encompass these treatment protocols.

MARKET SIZE FOR STEM CELL THERAPY IN SOUTH AMERICA

Incidence Market Size ( Billions )Disease Colombia Argentina Peru Brazil Venezuela Ecuador Chile Colombia Argentina Peru Brazil Venezuela Ecuador Chile Total market sizeDiabetes 54,255 48,532 35,054 230,126 34,454 18,317 20,254 $1.09 $0.97 $0.70 $4.60 $0.69 $0.37 $0.41 $8.82Lupus ,404 199,840 144,338 947,579 141,869 75,424 83,398 $4.47 $4.00 $2.89 $18.95 $2.84 $1.51 $1.67 $36.32Multiple sclerosis 62,006 55,466 40,061 263,001 39,376 20,934 23,147 $1.24 $1.11 $0.80 $5.26 $0.79 $0.42 $0.46 $10.08Crohns 79,787 71,371 51,549 338,421 50,667 26,937 29,785 $1.60 $1.43 $1.03 $6.77 $1.01 $0.54 $0.60 $12.97Scleroderma 47,872 42,823 30,930 203,052 30,400 16,162 17,871 $0.96 $0.86 $0.62 $4.06 $0.61 $0.32 $0.36 $7.78Myasthenia gravis 2,170 1,941 1,402 9,205 1,378 733 810 $0.04 $0.04 $0.03 $0.18 $0.03 $0.01 $0.02 $0.35Sickle cell anemia 43,404 38,826 28,043 184,101 27,563 14,654 16,203 $0.87 $0.78 $0.56 $3.68 $0.55 $0.29 $0.32 $7.06Leukemia 4,915 4,396 3,175 20,846 3,121 1,659 1,835 $0.10 $0.09 $0.06 $0.42 $0.06 $0.03 $0.04 $0.80Lymphoma 9,718 8,693 6,279 41,219 6,171 3,281 3,628 $0.19 $0.17 $0.13 $0.82 $0.12 $0.07 $0.07 $1.58Thalassemia 159 143 103 676 101 54 59 $0.00 $0.00 $0.00 $0.01 $0.00 $0.00 $0.00 $0.03

$10.5 Billion $9.5 Billion $7 Billion $45 Billion $7 Billion $4 Billion $86 Billion*Source : MarketResearch.com (Kalorama Information) ,WrongDiagnosis.com, World Health Organization**Average price per treatment of $20,000

223

Based at the University of California in San Diego, GIOSTAR is

recognized as one of the world’s leading stem cell research

laboratories. Over the years, they have been the beneficiary of more

than $400 million in research grants, endowment contributions and

legislative appropriations. They receive more than $50 million a year in

on-going funding commitments. GIOSTAR’s scientists are associated

with many leading medical research universities and institutions.

Bioscience Americas and GIOSTAR have entered into a Joint Venture

Agreement to own and operate a for-profit treatment wellness center

in Medellin, Colombia. Bioscience and GIOSTAR intend to participate

in additional joint ventures to own and operate for-profit clinics in

Brazil, Chile and eventually the United States.

Starting from this position as one of the world’s most respected stem

cell research consortiums, Bioscience and GIOSTAR intend to build and

promote the GIOSTAR brand as the world’s most recognized provider

of stem cell based treatments. This strategy is supported by the

paradigm shift occurring in health care today – toward a more patient

centered focus on treating diseases through a mastery of science as

opposed to surgery and symptom treatment with drugs.

THE GLOBAL INSTITUTE OF STEM CELL THERAPY AND RESEARCH

GIOSTAR’s scientists and researchers are associated with many

leading universities, research institutions, and hospitals including:

University of California at San Diego

University of California at Irvine

University of California at Los Angeles

National Research Institute, Japan

University Eye Hospital, Germany

Nansai Hospital, Japan

Vanderbilt University, Nashville

Case Western Reserve University, Cleveland

Harvard Medical School

Burnham Research Institute, San Diego

Salk Institute for Biological Studies, La Jolla, California

Our continuing research efforts provide our patients with the latest

in stem cell treatment care.

GIOSTAR’S UNIVERSITY AFFILIATIONS

FOR ADDITIONAL INFORMATION PLEASE CONTACT BIOSCIENCE AMERICAS, LLC(888) 623-0337 | BIOSCIENCEAMERICAS.COM© Copyright 2015 Bioscience Americas, LLC.

HOSPITAL UNIVERSITARIO SAN VICENTE DE PAUL

GLOBAL INSTITUTE OF STEM CELL THERAPY AND RESEARCH200 W ARBOR DR | SAN DIEGO, CA 92103 | 619.543.6222

PIONEERING STUDIES BYSTEM CELL RESEARCH TEAM• Our team was first in reporting the repair of Crohn’s disease damage using ES stem cells. (Biochemical Biophysical Research Communication, 361: 953-9, 2007). • Our team was first in reporting the repair of brain damage using ES stem cells. (Stemcells.7:1689-94, 2006). • Our research team successfully produced RBCs of high purity atexperimental levels in laboratory conditions from ES stem cells and concluded the significanceof WNT signaling pathways in hematopoietic differentiation from ES stem cells. (BiochemicalBiophysical ResearchCommunication,, 324:1333-9, 2004and Biochemical Biophysical Research Communication, 346:508-16, 2006).

• Our team was first in reporting the superiority of induced ES stem cells over adult stem cells after transplantation. (Transplantation, 78:174-82, 2004).

SAN VICENTE FUNDACIÓNRIONEGRO | ANTIOQUIA | COLOMBIA

GIOSTAR/BIOSCIENCE AMERICAS has established a collaborative relationship with Hospital Universitario San Vicente de Paul in Colombia. The hospital is part of the San Vicente Foundation, a non-profit medical network with more than 100 years of experience in providing highly complex health services.

There are two distinct hospitals as part of the Foundation’s network. The University Hospital is located in Medellin, Colombia. It has 660 beds, fourteen operating rooms and six intensive care units. The Hospital treats adults and children with the assistance of over twenty-five specialties and sixty-three sub-specialties.

The Specialized Center is located five minutes away from the international airport in Rionegro, 35 minutes from Medellin. The Rionegro hospital has three specialized centers:

The Cardiopulmonary and Peripheral Vascular Center

The Digestive Diseases Center

The Organ and Tissue Transplant Center